Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.

@article{Cho2014PatientsWC,
  title={Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.},
  author={Ju-Yeon Cho and Yong-Han Paik and Won Jun Sohn and Hyun Chin Cho and Geum-Youn Gwak and Moon Seok Choi and Joon Hyeok Lee and Kwang Cheol Koh and Seung Woon Paik and Byung Chul Yoo},
  journal={Gut},
  year={2014},
  volume={63 12},
  pages={1943-50}
}
BACKGROUND It is generally stated that oral antiviral therapy in patients with chronic hepatitis B (CHB) decreases the risk of developing hepatocellular carcinoma (HCC). Although oral nucleos(t)ide analogues (NUCs) may induce a state similar to inactive stage CHB, the long-term risk for HCC in patients treated with NUCs compared with inactive CHB is unclear. METHODS A total of 1378 patients who were treatment naïve and started NUC therapy and 1014 patients with inactive stage CHB who were… CONTINUE READING
41 Citations
18 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 18 references

Similar Papers

Loading similar papers…